Modality
Nanobody
MOA
C5i
Target
GPRC5D
Pathway
NF-κB
HS
Development Pipeline
Preclinical
Dec 2022
→ May 2025
PreclinicalCurrent
NCT07650997
1,800 pts·HS
2022-12→2025-05·Active
1,800 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-0611mo agoInterim· HS
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2
Preclinical
Active
Catalysts
Interim
2025-05-06 · 11mo ago
HS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07650997 | Preclinical | HS | Active | 1800 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| ASN-7408 | Ascendis Pharma | NDA/BLA | GPRC5D | |
| RVM-3746 | Revolution Medicines | Phase 1/2 | GPRC5D |